Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
BMJ Open
|
October 16, 2023
Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
Kristina Jenei, Daniel E Meyers
Journal of Cancer Policy
|
May 13, 2022
Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020
Kristina Jenei, Adam Raymakers, Daniel E Meyers, et al.
JAMA Internal Medicine
|
February 22, 2021
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada
Daniel E Meyers, Kristina Jenei, Timothy M Chisamore, et al.
Current Oncology (Toronto, Ont.)
|
December 13, 2021
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
Shantanu Banerji, Daniel E Meyers, Craig Harlos, et al.
Current Oncology (Toronto, Ont.)
|
September 27, 2024
Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials
Daniel E Meyers, Rebekah Rittberg, David E Dawe, et al.
Blood Cancer Journal
|
December 7, 2017
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
Daniel E Meyers, Satbir Thakur, Chandini M Thirukkumaran, et al.
Frontiers in Oncology
|
June 22, 2017
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
Daniel E Meyers, Amanda A Wang, Chandini M Thirukkumaran, et al.
Frontiers in Oncology
|
June 17, 2024
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study
Mehul Gupta, Igor Stukalin, Daniel E Meyers, et al.
Journal of Cancer Policy
|
May 13, 2022
Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets
Daniel E Meyers, Timothy M Chisamore, Matthew D F McInnes, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2026
Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease
Siddhartha Goutam, Arjun A Raghavan, Hans Alday, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
BMJ Open
|
October 16, 2023
Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
Kristina Jenei, Daniel E Meyers
Journal of Cancer Policy
|
May 13, 2022
Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020
Kristina Jenei, Adam Raymakers, Daniel E Meyers, et al.
JAMA Internal Medicine
|
February 22, 2021
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada
Daniel E Meyers, Kristina Jenei, Timothy M Chisamore, et al.
Current Oncology (Toronto, Ont.)
|
December 13, 2021
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
Shantanu Banerji, Daniel E Meyers, Craig Harlos, et al.
Current Oncology (Toronto, Ont.)
|
September 27, 2024
Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials
Daniel E Meyers, Rebekah Rittberg, David E Dawe, et al.
Blood Cancer Journal
|
December 7, 2017
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
Daniel E Meyers, Satbir Thakur, Chandini M Thirukkumaran, et al.
Frontiers in Oncology
|
June 22, 2017
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
Daniel E Meyers, Amanda A Wang, Chandini M Thirukkumaran, et al.
Frontiers in Oncology
|
June 17, 2024
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study
Mehul Gupta, Igor Stukalin, Daniel E Meyers, et al.
Journal of Cancer Policy
|
May 13, 2022
Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets
Daniel E Meyers, Timothy M Chisamore, Matthew D F McInnes, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 1, 2026
Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease
Siddhartha Goutam, Arjun A Raghavan, Hans Alday, et al.
Page
of 3